The thoracic oncology community is discussing results from the Phase III ELEVATE trial, published in NEJM, showing a significant disease-free survival benefit for adjuvant ensartinib in resected stage IB-IIIB ALK+ NSCLC. Also discussed are the negative results from the TREASURE trial, where adding consolidative thoracic radiotherapy to maintenance atezolizumab in extensive-stage SCLC failed to improve survival and increased toxicity. Additionally, there is commentary on the limited real-world efficacy of tarlatamab for patients with transformed EGFR mutant SCLC. A parallel thread debates trial-design ethics: @pash22 amplified a perspective by Timothee Olivier et al questioning whether the ethical argument for sham controls in Tumor Treating Fields trials (as used in LUNAR in NSCLC and in mesothelioma) holds up.
“In stage II-III, 2y DFS 86.4% vs 53.5% (HR 0.20).”
— @StephenVLiu · ELEVATE trial · View post ↗📌 Amplified by @KolPulseAI
“While DLL3 is highly expressed post-transformation, RWD with tarlatamab has shown limited efficacy.”
— @drshieldsmd · Tarlatamab in transformed SCLC · View post ↗📌 Amplified by @KolPulseAI
“In extensive-stage SCLC, adding consolidative thoracic radiotherapy to maintenance atezolizumab did not improve survival but increased serious and fatal toxicities, leading to early trial termination!”
— @dr_yakupergun · TREASURE trial · View post ↗📌 Amplified by @KolPulseAI
“Sham Controls and Tumor Treating Fields: Does the Ethical Argument Hold? via @Timothee_MD et al”
— @pash22 · TTFields trial-design ethics · View post ↗Quiet today — no notable KOL discussion in the last 48 hours.
Quiet today — no notable KOL discussion in the last 48 hours.
The GU conversation is led by the FDA approval of perioperative enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) for muscle-invasive bladder cancer, expanding use to cystectomy candidates regardless of cisplatin eligibility, based on KEYNOTE-B15/EV-304. Bladder-cancer KOLs are debating how broadly to apply it in cisplatin-eligible patients versus reserving it.
“The @US_FDA has approved perioperative EV + pembrolizumab for all patients with MIBC who are candidates for cystectomy, regardless of cisplatin eligibility”
— @neerajaiims · KEYNOTE-B15 / EV-304 FDA approval · View post ↗
“Now, the combo of EV-Pembro is @US_FDA approved for all muscle-invasive bladder cancer”
— @DrChoueiri · KEYNOTE-B15 / EV-304 FDA approval · View post ↗Myeloma KOLs are recapping the Best-of ASCO/EHA 2026 highlights, where bispecific antibodies were the major theme, alongside the FDA approval of an on-body injector for subcutaneous isatuximab (Sarclisa) — a second anti-CD38 that can be given subcutaneously.
“Teclistamab (± Dara) outperforms traditional triplets at 1st relapse”
— @rajshekharucms · Best of ASCO/EHA 2026 — myeloma bispecifics · View post ↗
“Just out: FDA approves isatuximab-irfc onbody injector subcutaneous injection for multiple myeloma.”
— @VincentRK · Isatuximab SC on-body approval · View post ↗Quiet today — no notable KOL discussion in the last 48 hours.